Serious and invasive pediatric pneumococcal disease: epidemiology and vaccine impact in the USA

References

• O’Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet374(9693), 893–902 (2009).
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Preventing pneumococcal diseases among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep.49(RR-9), 1–35 (2000).
   PubMedGoogle Scholar
• Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infect. Dis.5, 83–93 (2005).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H. Issues and challenges: pneumococcal vaccination in pediatrics. Pediatr. Ann.26, 355–360 (1997).
   PubMedGoogle Scholar
• Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J. Infect. Dis.174, 752–759 (1996).
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J. Infect. Dis.171, 885–889 (1995).
   PubMed Web of Science ®Google Scholar
• Hofmann J, Cetron MS, Farley MM et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N. Engl. J. Med.333, 481–486 (1995).
   PubMed Web of Science ®Google Scholar
• de Cunto Brandileone MC, Dias Vieira VS, Casagrande ST et al. Prevalence of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Microb. Drug Resist.3, 141–146 (1997).
   PubMedGoogle Scholar
• Levine MM, Lagos R, Levine OS et al. Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr. Infect. Dis. J.17, 287–293 (1998).
   PubMed Web of Science ®Google Scholar
• Rahav G, Toledano Y, Engelhard D et al. Invasive pneumococcal infections. A comparison between adults and children. Medicine76, 295–303 (1997).
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.46(RR-8), 1–24 (1997).
   PubMedGoogle Scholar
• Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA294, 2043–2051 (2005).
   PubMed Web of Science ®Google Scholar
• Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54, 893–897 (2005).
   PubMedGoogle Scholar
• Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine25, 2420–2427 (2007).
   PubMed Web of Science ®Google Scholar
• Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet356, 1210–1211 (2000).
   PubMed Web of Science ®Google Scholar
• Millar EV, O’Brien KL, Watt JP et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population. Clin. Infect. Dis.43, 8–15 (2006).
   PubMed Web of Science ®Google Scholar
• Ghaffar F, Barton T, Lozano J et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin. Infect. Dis.39, 930–938 (2004).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO Jr, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics113, 443–449 (2004).
   PubMed Web of Science ®Google Scholar
• Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis.197, 1016–1027 (2008).
   PubMed Web of Science ®Google Scholar
• Messina AF, Katz-Gaynor K, Barton T et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumonia isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J.26(6), 461–467 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez BE, Hulten KG, Lamberth L, Kaplan SL, Mason EO Jr; the US Pediatric Multicenter Pneumococcal Surveillance Group. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Pediatr. Infect. Dis. J.25(4), 301–305 (2006).
   PubMedGoogle Scholar
• Hausdorff W. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine25, 2406–2412 (2007).
   PubMed Web of Science ®Google Scholar
• Friedland IR. Antibiotic-resistant pneumococci. J. Pediatr.128, 862–863 (1996).
   PubMedGoogle Scholar
• Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am. Fam. Phys.55, 1647–1648 (1997).
   PubMed Web of Science ®Google Scholar
• Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med.354, 1455–1463 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobs NM. Pneumococcal osteomyelitis and arthritis in children. A hospital series and literature review. Am. J. Dis. Child.145, 70–74 (1991).
   PubMedGoogle Scholar
• Pineda SV, Perez BA, Domingo PM et al. Bacteremic pneumococal pneumonia. An. Esp. Pediatr.57(5), 408–413 (2002).
   PubMedGoogle Scholar
• Brandenbury JA, Marine TJ, Colez CM. Clinical presentation, processes and outcomes of care for patient with pneumococcal pneumonia. J. Gen. Intern. Med.15, 638–646 (2000).
   PubMedGoogle Scholar
• Mufson MA. Pneumococcal infections. JAMA246, 1942–1948 (1981).
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med.348, 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumcococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J.23(6), 485–489 (2004).
   PubMed Web of Science ®Google Scholar
• Shah SS, Ratner AJ. Trends in invasive pneumococcal disease-associated hospitalizations. Clin. Infect. Dis.42, e1–e5 (2006).
   PubMedGoogle Scholar
• Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J. Infect. Dis.196, 1346–1354 (2007).
   PubMed Web of Science ®Google Scholar
• Munoz-Almagro C, Jordan I, Gene A et al. Emergence of invasive pneumococcal disease caused by non-vaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis.46, 174–182 (2008).
   PubMed Web of Science ®Google Scholar
• Black S. Changing epidemiology of invasive pneumococcal disease: a complicated story. Clin. Infect. Dis.47, 485–486 (2008).
   PubMedGoogle Scholar
• Lacapa R, Bliss SJ, Larzelere-Hinton F et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococal conjugate vaccine. Clin. Infect. Dis.47, 476–484 (2008).
   PubMed Web of Science ®Google Scholar
• Ghaffar F, Friedland IR, McCracken GH Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr. Infect. Dis. J.18, 638–646 (1999).
   PubMed Web of Science ®Google Scholar
• Gray BM, Converse GM, Dillon HC. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J. Infect. Dis.142, 923–933 (1980).
   PubMed Web of Science ®Google Scholar
• Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001–2004. Pediatrics116, e408–e413 (2005).
   PubMed Web of Science ®Google Scholar
• Hanage WP, Huang SS, Lipsitch M, Bishop CJ, Godoy D, Pelton SI. Diversity and antibiotic resistance among nonvaccine serotypes of Streptococcus pneumonia carriage isolates in the post-heptavalent conjugate vaccine era. J. Infect. Dis.195, 347–352 (2007).
   PubMed Web of Science ®Google Scholar
• Miller EV, Watt JP, Bronsdon MA et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis.47, 989–996 (2008).
   PubMed Web of Science ®Google Scholar
• Hammitt LL, Bruden DL, Butler JC et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. J. Infect. Dis.193, 1487–1494 (2006).
   PubMed Web of Science ®Google Scholar
• Schuchat A, Robinson K, Wenger JD et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N. Engl. J. Med.337, 970–976 (1997).
   PubMed Web of Science ®Google Scholar
• Malley R, Ambrosino D. Pneumococcal diseases in children: morbidity, mortality, and resistance. University of Chicago Children’s Hospital Reports on Current Concepts in the Use of Pediatric Vaccines. 1, 1–8 (1998).
   Google Scholar
• Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr. Infect. Dis. J.12, 389–394 (1993).
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Griffin MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin. Infect. Dis.46, 1664–1672 (2008).
   PubMed Web of Science ®Google Scholar
• Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med.360, 244–256 (2009).
   PubMed Web of Science ®Google Scholar
• Jacobs NM, Lerdkachornsuk S, Metzger WI. Pneumococcal bacteremia in infants and children:a ten-year experience at the Cook County Hospital with special reference to the pneumococcal serotypes isolated. Pediatrics64, 296–300 (1979).
   PubMed Web of Science ®Google Scholar
• Lee GM, Harper MB. Risk of bacteremia for febrile young children in the post Haemophilus inlfuenzae type B era. Arch. Pediatr. Adolesc. Med.152, 624–628 (1999).
   Google Scholar
• Davidson M, Schraer CD, Parkinson AJ et al. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA261, 715–718 (1989).
   PubMed Web of Science ®Google Scholar
• Kuppermann N, Fleisher GR, Jaffe DM. Predictors of occult pneumococcal bacteremia in young febrile children. Ann. Emerg. Med.31, 679–687 (1998).
   PubMed Web of Science ®Google Scholar
• Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA295, 1668–1674 (2006).
   PubMed Web of Science ®Google Scholar
• Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bactermia. Clin. Infect. Dis.42, 907–914 (2006).
   PubMed Web of Science ®Google Scholar
• Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. Semin. Resp. Infect.14(3), 227–236 (1999).
   PubMedGoogle Scholar
• Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J.21(9), 810–815 (2002).
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet369, 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch. Pediatr. Adolesc. Med.161(12), 1162–1168 (2007).
   PubMed Web of Science ®Google Scholar
• Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine – United States, 1997–2006. MMWR Morb. Mortal. Wkly. Rep.58(01), 1–4 (2009).
   PubMedGoogle Scholar
• Nelson JC, Jackson M, Yu Onchee et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine26, 4947–4954 (2008).
   PubMed Web of Science ®Google Scholar
• Bradley JS, Kaplan SL, Tan TQ et al. Pediatric pneumococcal bone and joint infections. Pediatrics102, 1376–1382 (1998).
   PubMedGoogle Scholar
• Jacobs NM. Pneumococcal osteomyelitis and arthritis in children. A hospital series and literature review. Am. J. Dis. Child.145, 70–74 (1991).
   PubMedGoogle Scholar
• Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J.26, 123–128 (2007).
   PubMed Web of Science ®Google Scholar
• Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccine on antibiotic resistance. Lancet Infect. Dis.8, 785–795 (2008).
   PubMed Web of Science ®Google Scholar
• Pai R, Moore MR, Pilishvili T et al. Postvaccine genetic structure of Streptococcus pneumonia 19A from children in the United States. J. Infect. Dis.192, 1988–1995 (2005).
   PubMed Web of Science ®Google Scholar
• Dagan R. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Clin. Microbiol. Infect.15(Suppl. 3), 16–20 (2009).
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med.325, 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Rubin LG. Pneumococcal vaccine. Pediatr. Clin. North Am.47, 269–285 (2000).
   PubMed Web of Science ®Google Scholar
• Shinefield HR, Black S, Ray P et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J.18, 757–763 (1999).
   PubMed Web of Science ®Google Scholar
• Wuorimaa T, Dagan R, Eskola J et al. Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers. Pediatr. Infect. Dis. J.120, 272–277 (2001).
   Google Scholar
• Klugman KP, Madhi SA, Huebner RE. A trial of a 9 valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med.349, 1341–1348 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Zamir O et al. Reduction of nasopharyngeal carriage of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J. Infect. Dis.185, 927–936 (2002).
   PubMed Web of Science ®Google Scholar
• Sigurdardottir ST, Davidsdottir K, Arason VA et al. Safety and immunogenicity of CRM 197 conjugated pneumococcal-meningococcal C combination vaccine (PVPnC-MnCC) whether given in two or three primary doses. Vaccine26(33), 4178–4186 (2008).
   PubMed Web of Science ®Google Scholar
• Copeding MZR, Puumalaimen T, Gepanayao CP et al. Safey and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein conjugated pneumococcal vaccine in Filipino infants. BMC Infect. Dis.3, 17–22 (2003).
   PubMedGoogle Scholar
• Puumalainer T, Zeta-Copeding MR, Kajhty H et al. Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr. Infect. Dis. J.21, 309–316 (2002).
   PubMedGoogle Scholar
• Bermal N, Szenborn L, Chrobot A et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr. Infect. Dis. J.28(4), S89–S96 (2009).
   PubMed Web of Science ®Google Scholar
• Dinleyici EC, Yargic ZA. Current knowledge regarding investigational 13-valent pneumococcal conjugate vaccine. Expert Rev. Vaccines8(8), 977–986 (2009).
   PubMed Web of Science ®Google Scholar
• Cao J, Chen D, Xu W et al. Enhanced protection against pneumococcal infection elicited by immunization with the combination PspA, PspC and ClpP vaccine. Vaccine25(27), 4996–5005 (2007).
   PubMed Web of Science ®Google Scholar
• Ming C, Lin H, Huang J et al. Development of 5-valent conjugate pneumococcal protein A-capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease. Microb. Pathog.47(3), 151–156 (2009).
   PubMedGoogle Scholar
• Arevalo MT, Xu O, Paton JC et al. Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunol. Med. Microbiol.55(3), 346–351 (2009).
   PubMed Web of Science ®Google Scholar